Equities Research Analysts’ Updated EPS Estimates for December, 19th (AAPL, ABT, AMZN, AXTA, CMA, CRTO, DPSGY, HZN, IBM, ORCL)
Apple (NASDAQ:AAPL) had its neutral rating reissued by analysts at Instinet. The firm currently has a $175.00 price target on the stock.
Abbott Laboratories (NYSE:ABT) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Post a promising third-quarter performance by Abbott, we are optimistic about the strong and consistent EPD and Medical Devices performance. However, the ongoing sluggish trend in the Nutrition business is a downside. However, the company continues to benefit from the recently completed St. Jude Medical buyout. Meanwhile, Alere acquisition close is an upside too. Through 2017, Abbott is effectively focusing on core therapeutic areas. Recently, its FreeStyle Libre Flash received the FDA approval. Also, it has received approval for MR-conditional labeling for Ellipse ICD. Also, emerging market performance remains promising on several new strategic developments. Hence, in the past three months, Abbott is trading above the broader industry. On the flip side, sluggish pediatric nutrition business in some global markets continues to dent growth. Also the economic problems in Venezuela are expected to remain unresolved.”
Raymond James Financial, Inc. started coverage on shares of Axalta Coating Systems (NYSE:AXTA). Raymond James Financial, Inc. issued a market perform rating on the stock.
UBS AG started coverage on shares of Axalta Coating Systems (NYSE:AXTA). They issued a market perform rating on the stock.
Comerica (NYSE:CMA) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Shares of Comerica have outperformed the industry year to date. This is backed by the company's impressive earnings surprise history. It surpassed the Zacks Consensus Estimate for earnings in each of the trailing four quarters. The company’s future prospects look promising as it improvised the financial targets for revenues and efficiency initiatives (GEAR Up). Also, its steady capital deployment activities continue to enhance investors’ confidence. Moreover, following the recent Fed interest rate hike, the company raised its prime lending rate to 4.50% from 4.25%., which is likely to further support Comerica's easing margin pressure. However, a stretched valuation indicates that the stock has limited upside potential. Also, significant exposure to commercial loans keeps us apprehensive.”
Criteo (NASDAQ:CRTO) had its market perform rating reaffirmed by analysts at Cowen Inc. They currently have a $25.00 price target on the stock, down from their previous price target of $40.00.
Deutsche Post (OTCMKTS:DPSGY) had its buy rating reissued by analysts at Morgan Stanley.
Barrington Research began coverage on shares of Horizon Global (NYSE:HZN). The firm issued an outperform rating and a $23.00 target price on the stock.
International Business Machines (NYSE:IBM) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “IBM provides advanced information technology solutions, including computer systems, software, storage systems and microelectronics. Shares of the company have underperformed the industry over the past one year. IBM is having a tough time, given the ongoing and heavily time-consuming business model transition to cloud. Further, sluggish IT spending particularly on on-premise and data center hardware and foreign exchange volatility remain concerns. Moreover, intensifying competition in most of the markets is a major concern. Nonetheless, IBM is benefiting from robust performance of cognitive solutions, which are driven by strong demand for security, IoT and analytics offerings. Moreover, continuing strength in cloud, mobile, security and analytics as well as cost savings are expected to drive profitability. The company’s expanding footprint in the rapidly growing blockchain market is positive in our view. “
Oracle (NYSE:ORCL) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Oracle reported encouraging second-quarter results, with both the top and bottom line surpassing the Zacks Consensus Estimate. Also, year-over-year comparisons on both counts were favourable. Oracle’s top-line growth benefited from the ongoing cloud-based momentum. However, the company’s soft cloud outlook for the third quarter reflects intensifying competition from Microsoft Azure and Amazon Web Services (AWS) in the cloud. Moreover, higher investments on PaaS and IaaS will keep margins under pressure in the near term. Further, a strong U.S. dollar remains a headwind. Shares of the company have also underperformed the industry on a year-to-date basis. Nevertheless, we believe that the company is benefiting from significant momentum in the SaaS offerings. Moreover, the next-generation autonomous database, which is supported by machine learning, is a key catalyst.”
Dougherty & Co assumed coverage on shares of Paylocity (NASDAQ:PCTY). They issued a neutral rating on the stock.
Dougherty & Co initiated coverage on shares of PFSweb (NASDAQ:PFSW). They issued a buy rating and a $9.00 target price on the stock.
Deutsche Bank AG assumed coverage on shares of Procter & Gamble (NYSE:PG). The firm issued a buy rating and a $91.88 target price on the stock.
Pinnacle Entertainment (NASDAQ:PNK) had its neutral rating reaffirmed by analysts at Susquehanna Bancshares Inc.
Raymond James Financial, Inc. began coverage on shares of PPG Industries (NYSE:PPG). They issued an outperform rating and a $139.00 price target on the stock.
KeyCorp initiated coverage on shares of Redfin (NASDAQ:RDFN). They issued a sector weight rating on the stock.
Instinet assumed coverage on shares of Sucampo Pharmaceuticals (NASDAQ:SCMP). The firm issued a buy rating and a $43.00 target price on the stock.
Raymond James Financial, Inc. began coverage on shares of Sherwin-Williams (NYSE:SHW). They issued a strong-buy rating and a $496.00 price target on the stock.
BIO-TECHNE (NASDAQ:TECH) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising quantikine kits; and clinical diagnostic immunoassay kits. The Company also offers flow cytometry products; natural and synthetic chemical compounds; hematology controls and calibrators; and hematology control products. Bio-Techne Corporation, formerly known as Techne Corporation, is headquartered in Minneapolis, Minnesota. “
Ultrapar Participacoes (NYSE:UGP) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Ultrapar Participacoes S.A., a major Brazilian industrial group, is one of the largest distributors of liquefied petroleum gas in Brazil and a leading producer of petrochemicals and chemical. Ultrapar is also engaged in the storage and transportation of liquefied petroleum gas and petrochemical and chemical products. (PRESS RELEASE) “
Receive News & Ratings for Apple Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apple Inc and related companies with MarketBeat.com's FREE daily email newsletter.